Noxopharm Announces Publication of LuPIN Trial Data in the European Urology Oncology Journal

Summary

• Noxopharm announced peer-reviewed publication of key LuPIN (Phase 2) study data in the European Urology Oncology journal.
• The authors of publication concluded that the combination treatment of ¹⁷⁷LuPSMA-617 and Veyonda^® is a safe treatment for late-stage prostate cancer patients.
• The combination treatment delivered promising efficacy outcomes, including a median Overall Survival of 17.1 months, compared to only 4.5 months in men who have exhausted all standard treatment options.
• The publication supports the growing evidence that Veyonda^® holds the potential to become a standard of care drug in late-stage prostate cancer.

Clinical-stage drug development player, Noxopharm Limited (ASX:NOX) has recently announced peer-reviewed publication of the LuPIN trial data in the international journal, European Urology Oncology.

According to Noxopharm, the publication of key LuPIN (Phase 2) study data strengthens the case for the Company’s lead product candidate, Veyonda^® as a safe and potentially life-prolonging treatment in late-stage prostate cancer.

The peer-reviewed publication outlines the details of the LuPIN study, its background, design, treatment interventions and the results for the first 32 patients in 56-patient study.

What is LuPIN Study?

The LuPIN study is an investigator-initiated Phase 1b/2a clinical trial evaluating the Veyonda^® in combination with an experimental radiopharmaceutical therapy owned by Novartis, ¹⁷⁷Lu-PSMA-617, in patients suffering from end-stage metastatic castration-resistant prostate cancer (mCRPC) who have limited survival chances and have exhausted all standard treatment options.

Noxopharm’s LuPIN study is considerably different from several others as it is examining ¹⁷⁷Lu-PSMA-617 therapy in specifically those patients who have stopped responding to all other standard therapies. However, other studies often use patients with remaining treatment options.

Independent Publication of LuPIN trial in International Journal

Noxopharm reported that the first manuscript of the LuPIN trial has been published in the European Urology Oncology journal. This is the first official publication of the European Association of Urology that is completely devoted to the study of genitourinary cancer.

The publication has been peer-reviewed by a panel of experts in the field. The authors include prominent medical experts from the Garvan Institute of Medical Research, Kinghorn Cancer Centre, Monash University, St Vincent’s Hospital Sydney, Princess Margaret Cancer Center (Toronto) and Sir Peter MacCallum Dept of Oncology.

Publication Supports Veyonda^®’s Potential in Late-Stage Prostate Cancer

The authors of the publication concluded that a combination treatment of ¹⁷⁷LuPSMA-617 and Veyonda^® is a safe treatment for late-stage prostate cancer patients who have exhausted all standard treatment options.

The authors also noted that the combination treatment delivered promising efficacy outcomes, including a median Overall Survival of 17.1 months. The result denotes a triple increase, in comparison to the median Overall Survival of only 4.5 months in a study conducted in a similar patient population (progressive disease, exhausted all standard treatment options) receiving standard chemotherapy.

Additionally, the ¹⁷⁷Lu-PSMA-617 therapy is also attracting substantial international attention as a promising therapy for men suffering from Stage 4 prostate cancer. Noxopharm notified that the therapy was the subject of a USD 6 billion series of acquisitions by Novartis in 2018. Notably, Noxopharm expects it become a commercially available drug next year.

The independent publication of LuPIN trial supports the growing evidence that Veyonda^® holds the potential to become a standard of care drug in late-stage prostate cancer, especially given that the combination was well-tolerated, even in patients with very limited survival prospects and advanced disease.

NOX traded at $0.320 on 12 August 2020 ( 3:58 PM AEST).